Positives

• A Long COVID patient who pursued psilocybin microdosing described it as helping her start exercising regularly again, supporting some functional recovery alongside her conventional treatments LDN Research Trust.
  
  

Negatives

• Patients with treatment-resistant depression who tried microdosing on their own (rather than full-dose therapy) commonly report no benefit, with one describing the experience as “mainly irritable and cranky” PMC.
• For chronic-pain patients, microdosing can have an uncomfortable stimulant effect that worsens pain perception, and some clinicians explicitly recommend supervised macro-dose therapy instead for that subset.
  
  

Hurdles & Side Effects

• Psilocybin remains Schedule I in the US (with limited carve-outs in Oregon and Colorado for adult-supervised use); microdosing access typically requires either underground sourcing or travel to a legal jurisdiction, with no quality control on potency PsyPost.
  
  
• Microdosing protocols typically use 50-200 mg of dried mushrooms (roughly 1/10th of a recreational dose) every 3 days; patients with personal or family history of psychotic-spectrum disorders should avoid microdosing because even sub-perceptual doses can theoretically destabilize Frontiers in Psychiatry.